Document Detail


Inflammatory mediators in induced sputum and airway hyperresponsiveness in cough variant asthma during long-term inhaled corticosteroid treatment.
MedLine Citation:
PMID:  22927709     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: This study aimed to investigate improvements in inflammatory mediator levels in induced sputum and airway hyperresponsiveness (AHR) in cough variant asthma (CVA) during long-term inhaled corticosteroid (ICS) treatment.
PATIENTS AND METHODS: Patients with CVA (N = 35) and classic asthma (N = 26) and healthy subjects (N = 24) were recruited into this study. All patients were treated with budesonide (400 μg/day). Measurement of inflammatory mediators in induced sputum and PD20-FEV(1) (the accumulated provocative dose resulting in a 20% decrease in FEV(1)) in histamine-challenged subjects was performed every three months after the start of medication. Interleukin- (IL-) 5 and IL-10 were assayed by ELISA, and the percentage of eosinophils was detected with Giemsa stain. Trends during the follow-up period were analyzed using a general linear model.
RESULTS: Inflammatory mediator levels in induced sputum and PD20-FEV(1) in patients with CVA and classic asthma differed from those in the control group, although no differences were found in the two asthmatic groups. PD20-FEV(1) significantly increased in CVA patients after ICS treatment for 3 months, while classic asthma patients exhibited a delayed change in AHR. After ICS treatment, levels of IL-5 and IL-10 as well as the percentage of eosinophils in the CVA group were altered at 3 months and 6 months, respectively. Accordingly, the level of inflammatory mediators in classic asthma changed more slowly.
CONCLUSION: CVA has a greater improvement in airway inflammation and airway hyperresponsiveness (AHR) than classic asthma with respect to inhaled corticosteroid (ICS). Short-term ICS considerably reduces AHR although longer treatment is required for complete control of airway inflammation.
Authors:
Meixuan Liu; Kaixiong Liu; Ning Zhu; Jingwen Xia; Xiaodong Chen
Related Documents :
20703849 - Favorable clinical outcome using a covered stent following transjugular intrahepatic po...
16671489 - Clinical outcome of patients with idiopathic normal pressure hydrocephalus three years ...
20939039 - Coil closure of residual shunt after amplatzer pfo occlusion.
1984509 - Shunt surgery for hydrocephalus in tuberculous meningitis: a long-term follow-up study.
10520919 - Surgical portosystemic shunts for treatment of portal hypertensive bleeding: outcome an...
6872799 - Budd-chiari syndrome associated with oral contraceptive steroids. review of treatment o...
23741689 - Antiadhesive effect and safety of oxidized regenerated cellulose after thyroidectomy: a...
19034249 - Spinal anesthesia for transurethral resection operations: bupivacaine versus levobupiva...
24082979 - Navilas laser system focal laser treatment for diabetic macular edema - one year result...
Publication Detail:
Type:  Journal Article     Date:  2012-08-08
Journal Detail:
Title:  Mediators of inflammation     Volume:  2012     ISSN:  1466-1861     ISO Abbreviation:  Mediators Inflamm.     Publication Date:  2012  
Date Detail:
Created Date:  2012-08-28     Completed Date:  2012-11-28     Revised Date:  2013-07-12    
Medline Journal Info:
Nlm Unique ID:  9209001     Medline TA:  Mediators Inflamm     Country:  United States    
Other Details:
Languages:  eng     Pagination:  403868     Citation Subset:  IM    
Affiliation:
Department of Respiratory Disease, Huashan Hospital, Fudan University, Shanghai 200040, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Inhalation
Adrenal Cortex Hormones / administration & dosage,  therapeutic use*
Adult
Asthma / drug therapy,  metabolism*
Cough / drug therapy,  metabolism*
Enzyme-Linked Immunosorbent Assay
Female
Humans
Inflammation Mediators / metabolism*
Interleukin-10 / metabolism
Interleukin-5 / metabolism
Male
Middle Aged
Sputum / metabolism*
Chemical
Reg. No./Substance:
0/Adrenal Cortex Hormones; 0/Inflammation Mediators; 0/Interleukin-5; 130068-27-8/Interleukin-10
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Serum levels of asymmetric dimethylarginine and apelin as potential markers of vascular endothelial ...
Next Document:  Genetic markers of cardiovascular disease in rheumatoid arthritis.